Published in J Clin Oncol on May 16, 2011
STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT (2014) 1.24
Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells. J Biol Chem (2013) 1.15
Prognostic or predictive? It's time to get back to definitions! J Clin Oncol (2011) 1.04
STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. Mol Cell Endocrinol (2013) 1.04
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer (2015) 1.03
Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife (2013) 1.02
Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res (2011) 1.01
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res (2012) 0.96
Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene (2013) 0.95
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Res Notes (2013) 0.91
Global profiling of prolactin-modulated transcripts in breast cancer in vivo. Mol Cancer (2013) 0.90
Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells. PLoS One (2015) 0.85
STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases. Neoplasia (2012) 0.85
Stat5: from breast development to cancer prognosis, prediction, and progression. J Clin Oncol (2011) 0.84
STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol (2013) 0.84
STAT signaling in different breast cancer sub-types. Mol Cell Endocrinol (2013) 0.83
Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse. Adv Exp Med Biol (2015) 0.83
Coffee polyphenols change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells. Oxid Med Cell Longev (2012) 0.81
Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Res (2013) 0.80
Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene (2015) 0.79
Increased STAT1 signaling in endocrine-resistant breast cancer. PLoS One (2014) 0.78
Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas. Oncogene (2013) 0.77
Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity. J Biol Chem (2016) 0.77
Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer (2013) 0.77
Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Mod Pathol (2016) 0.76
Prolactin signaling through focal adhesion complexes is amplified by stiff extracellular matrices in breast cancer cells. Oncotarget (2016) 0.76
Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors. Int J Mol Sci (2017) 0.75
Prolactin Inhibits BCL6 Expression in Breast Cancer Cells through a MicroRNA-339-5p-Dependent Pathway. J Breast Cancer (2016) 0.75
Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Res (2017) 0.75
Enhanced T cell lymphoma in NOD.Stat5b transgenic mice is caused by hyperactivation of Stat5b in CD8+ thymocytes. PLoS One (2013) 0.75
The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One (2015) 0.75
Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification. Proc Natl Acad Sci U S A (2017) 0.75
STAT3 activation in infection and infection-associated cancer. Mol Cell Endocrinol (2017) 0.75
JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition. JAKSTAT (2013) 0.75
The prognostic values of signal transducers activators of transcription family in ovarian cancer. Biosci Rep (2017) 0.75
Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models. J Steroid Biochem Mol Biol (2017) 0.75
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 6.22
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev (1997) 5.57
Tamoxifen in the treatment of breast cancer. N Engl J Med (1998) 4.75
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst (2005) 3.62
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol (2003) 3.58
Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J (1994) 3.32
Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci U S A (1995) 2.79
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res (2005) 2.60
Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev (2001) 2.54
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res (2004) 2.15
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst (2007) 2.11
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res (2003) 1.96
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res (2004) 1.89
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res (2006) 1.87
Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol (2004) 1.78
Ultrahigh density microarrays of solid samples. Nat Methods (2005) 1.77
Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene (2005) 1.76
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol (1992) 1.76
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst (2006) 1.74
Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer (2004) 1.60
Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res (2006) 1.43
Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res (2002) 1.38
Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ (1999) 1.38
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol (2008) 1.37
Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer (1988) 1.37
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast (2005) 1.32
Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene (2002) 1.30
Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis. Appl Immunohistochem Mol Morphol (2009) 1.25
Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer (2006) 1.24
Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res (2006) 1.23
Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol (2002) 1.22
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol (2007) 1.04
Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci (2008) 1.01
Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer (2009) 0.99
Automated analysis of tissue microarrays. Methods Mol Biol (2010) 0.99
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol (2003) 0.97
Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells. J Biol Chem (2002) 0.96
STAT 5a expression in various lesions of the breast. Virchows Arch (2005) 0.90
A prognostic index for operable, node-negative breast cancer. Br J Cancer (2004) 0.89
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res (2009) 0.87
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 6.22
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 4.69
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst (2005) 3.62
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med (2012) 3.29
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 3.15
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle (2011) 2.92
Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle (2011) 2.91
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle (2010) 2.80
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol (2004) 2.74
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening. Cancer (2007) 2.64
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Long-term preservation of antigenicity on tissue microarrays. Lab Invest (2004) 2.44
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol (2008) 2.43
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol (2005) 2.43
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A (2009) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle (2011) 2.39
Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest (2009) 2.37
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle (2010) 2.32
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
Assessing semantic similarity measures for the characterization of human regulatory pathways. Bioinformatics (2006) 2.29
Genome-wide association study dissects the genetic architecture of oil biosynthesis in maize kernels. Nat Genet (2012) 2.25
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther (2009) 2.25
Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res (2011) 2.08
The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle (2010) 2.07
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer (2002) 2.04
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer (2006) 2.00
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res (2003) 1.96
RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (2010) 1.96
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov (2012) 1.94
Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res (2006) 1.91
MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci U S A (2007) 1.90
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A (2009) 1.89
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 1.87
The genomic heritage of lymph node metastases: implications for clinical management of patients with breast cancer. Ann Surg Oncol (2008) 1.87
Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol (2009) 1.87
The reliability of telephone interviews compared with in-person interviews using memory aids. Ann Epidemiol (2003) 1.86
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (2009) 1.83
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res (2004) 1.80
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther (2008) 1.79
Tailored navigation in colorectal cancer screening. Med Care (2008) 1.79
Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol (2004) 1.78
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol (2006) 1.78
Ultrahigh density microarrays of solid samples. Nat Methods (2005) 1.77
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77